<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Committee</title>
	<atom:link href="http://www.tapanray.in/tag/committee/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Price Negotiation For Patented Drugs: Still Continues A Policy Paralysis</title>
		<link>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=price-negotiation-for-patented-drugs-continues-a-policy-paralysis</link>
		<comments>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/#comments</comments>
		<pubDate>Mon, 12 Dec 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[policy Paralysis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8006</guid>
		<description><![CDATA[Many poor and even middle-income patients, who spend their entire life savings for treatment of life-threatening ailments, such as, cancer, have been virtually priced out of the access to patented new drugs, across the world. As articulated by the American &#8230; <a href="http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ease of Doing Pharma Business in India: A Kaleidoscopic View </title>
		<link>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view</link>
		<comments>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/#comments</comments>
		<pubDate>Mon, 28 Mar 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doing]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ease]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irration]]></category>
		<category><![CDATA[Kaleidoscope]]></category>
		<category><![CDATA[Kaleidoscopic]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7552</guid>
		<description><![CDATA[Ensuring ease of doing any ethical business activity in India, is a new focus area of the Government and is very rightly so. Creating ease of doing ethical pharma business too, falls under this overall national objective. In this article, &#8230; <a href="http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Recent Ban On Irrational FDCs: History Repeats Itself</title>
		<link>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-recent-ban-on-irrational-fdcs-history-repeats-itself</link>
		<comments>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/#comments</comments>
		<pubDate>Mon, 21 Mar 2016 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[294]]></category>
		<category><![CDATA[344]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[ADE]]></category>
		<category><![CDATA[ADR]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Corex]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[FDCs]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[injunction]]></category>
		<category><![CDATA[interim]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[itself]]></category>
		<category><![CDATA[Kokate]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repeats]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sri Lanka]]></category>
		<category><![CDATA[stay]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7543</guid>
		<description><![CDATA[The recent regulatory ban on a large number of irrational Fixed Dose Combination (FDC) drugs is not a new incident in India. A similar mega ban was announced even before, about nine years ago. Intriguingly, the saga continues, for various &#8230; <a href="http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Drug Safety Concern: “Whistleblower’s Intention Should Be Nationalistic”</title>
		<link>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic</link>
		<comments>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/#comments</comments>
		<pubDate>Mon, 14 Mar 2016 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[Anti-nationalistic]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dinesh]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thakur]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whistleblower]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7529</guid>
		<description><![CDATA[In the recent weeks, three significant developments related to the Pharmaceutical Industry in India, have triggered rejuvenated concerns in the following critical areas:  A. Overall drug safety standards in the country B.  Self serving interest, rather than patients’ interest, dominate &#8230; <a href="http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Against Pharma Marketing Malpractices: A Gutsy Step</title>
		<link>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=against-pharma-marketing-malpractices-a-gutsy-step</link>
		<comments>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/#comments</comments>
		<pubDate>Mon, 22 Feb 2016 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[58th]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Clinton]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[conflit]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dollars for doc]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[follow]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Gutsy]]></category>
		<category><![CDATA[Hilary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharnaceuticals]]></category>
		<category><![CDATA[Physician Payments Sunshine Act]]></category>
		<category><![CDATA[ProPublica]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7447</guid>
		<description><![CDATA[January 7, 2016 edition of ‘The Financial Times (FT)’ reported that responding to escalating pressure on the drug industry, related to its ‘Conflict of Interest’ with the doctors and other related professionals, GlaxoSmithKline (GSK) has decided taking a very unorthodox &#8230; <a href="http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Just 16% Of Indian Population Has Access To Free Or Partially-Free Health Care?</title>
		<link>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=just-16-of-indian-population-has-access-to-free-or-partially-free-health-care</link>
		<comments>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/#comments</comments>
		<pubDate>Mon, 05 Oct 2015 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[16]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[2015-14]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[BRICS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[debates]]></category>
		<category><![CDATA[Dengue]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[partially]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Rangarajan]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRP]]></category>
		<category><![CDATA[TV]]></category>
		<category><![CDATA[up-market]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7121</guid>
		<description><![CDATA[Is health care currently a low priority area for the Government of India? Probably yes, and thus it is worth trying to fathom it out. Besides planned frugal spending on overall public health in 2015-16, even as compared to the past &#8230; <a href="http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s China Dependence On API: A Time To Think ‘Outside The Box’</title>
		<link>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-china-dependence-on-api-a-time-to-think-outside-the-box</link>
		<comments>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/#comments</comments>
		<pubDate>Mon, 21 Sep 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[Advisor]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[out of box]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[year of API]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7086</guid>
		<description><![CDATA[The Department of Pharmaceuticals (DoP) has declared the Year 2015 as the Year of ‘Active Pharmaceutical Ingredient (API)’. Following it up on February 25, 2015, the Union Minister of Chemicals &#38; Fertilizers Ananth Kumar assured the Pharmaceutical Industry that appropriate &#8230; <a href="http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Booming Sales Of Unapproved Drugs: Do We Need “Safe In India” Campaign For Medicines?</title>
		<link>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines</link>
		<comments>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/#comments</comments>
		<pubDate>Mon, 18 May 2015 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Abraham]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[booming]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[Lincoln]]></category>
		<category><![CDATA[may]]></category>
		<category><![CDATA[medicines. PLOS]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Peer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reviewed]]></category>
		<category><![CDATA[Safe in India]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Statement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unapproved]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6622</guid>
		<description><![CDATA[“To sin by silence when they should protest makes cowards of men”                      - Abraham Lincoln Not just the Federal Drug Administration of the United States (USFDA), global concerns are being expressed &#8230; <a href="http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does ‘Free-Market Economy’ Work For Branded Generic Drugs In India?</title>
		<link>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-free-market-economy-work-for-branded-generic-drugs-in-india</link>
		<comments>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 27 Apr 2015 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Badm Medicine]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[chemicals. and. fertilizers]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Delhi School of Economics]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DSE]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Free Market Economy]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[IJME]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradox]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[‘Dorfman-Steiner’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6557</guid>
		<description><![CDATA[On April 20, 2015, a panel of 31 lawmakers of the Standing Committee on Chemicals and Fertilizers tabled its report in the Indian Parliament. The committee emphasized that patients in India should have access to all medicines, including life saving drugs, &#8230; <a href="http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
